Royalty Pharma (RPRX) Cash & Equivalents (2019 - 2026)
Royalty Pharma (RPRX) posted Cash & Equivalents of $586.4 million for Q1 2026, down 5.22% sequentially from $618.7 million in Q4 2025, and down 46.09% YoY from $1.1 billion in Q1 2025.
Royalty Pharma (RPRX) Cash & Equivalents (2019 - 2026) Analysis & Trends
Royalty Pharma has reported Cash & Equivalents for 8 years, with the latest figure at $586.4 million in Q1 2026.
- Quarterly Cash & Equivalents fell 46.09% year-over-year to $586.4 million in Q1 2026, while the trailing twelve-month figure through Mar 2026 was $586.4 million (down 46.09% YoY) and the FY2025 annual result came in at $618.7 million, down 33.4% from the prior year.
- Cash & Equivalents declined to $586.4 million in Q1 2026 per RPRX's latest filing, from $618.7 million in the prior quarter.
- Over five years, Cash & Equivalents peaked at $2.2 billion in Q2 2023 and troughed at $477.0 million in Q4 2023.
- A 5-year average of $1.2 billion and a median of $950.1 million in 2024 frame the typical range for Cash & Equivalents.
- The sharpest annual moves came in 2022 and 2023: Cash & Equivalents soared 152.75% in 2022, then sank 72.12% in 2023.
- Over 5 years, Cash & Equivalents stood at $1.7 billion in 2022, then tumbled by 72.12% to $477.0 million in 2023, then surged by 94.76% to $929.0 million in 2024, then plunged by 33.4% to $618.7 million in 2025, then decreased by 5.22% to $586.4 million in 2026.
- According to Business Quant data, Cash & Equivalents over the past three periods registered $586.4 million, $618.7 million, and $938.9 million for Q1 2026, Q4 2025, and Q3 2025 respectively.
Powered by 
Peer Comparison
| # | Company | Market Cap | Enterprise Value | Gross Profit (Qtr) | Cash & Equiv. (Qtr) |
|---|---|---|---|---|---|
| 1 | Vertex Pharmaceuticals | 128.13 Bn | 120.28 Bn | 2.84 Bn | 6.14 Bn |
| 2 | Regeneron Pharmaceuticals | 112.33 Bn | 104.33 Bn | 3.93 Bn | 2.46 Bn |
| 3 | Argenx Se | 53.24 Bn | 48.05 Bn | 1.41 Bn | 3.58 Bn |
| 4 | Revolution Medicines | 43.64 Bn | 43.64 Bn | - | 815.44 Mn |
| 5 | BeOne Medicines | 39.27 Bn | 34.17 Bn | 1.53 Bn | 5.10 Bn |
| 6 | MindWalk Holdings | 35.32 Bn | 35.31 Bn | 1.82 Bn | 8.37 Mn |
| 7 | Royalty Pharma | 33.72 Bn | 35.84 Bn | - | 811.99 Mn |
| 8 | Alnylam Pharmaceuticals | 30.58 Bn | 27.27 Bn | 992.69 Mn | 1.71 Bn |
| 9 | Insmed | 27.01 Bn | 25.85 Bn | 358.27 Mn | 544.80 Mn |
| 10 | Roivant Sciences | 26.16 Bn | 26.85 Bn | 1.16 Mn | 1.25 Bn |
Historic Data
Download Data| Date | Value |
|---|---|
| Jun 30, 2026 | 811.99 Mn |
| Mar 31, 2026 | 586.40 Mn |
| Dec 31, 2025 | 618.70 Mn |
| Sep 30, 2025 | 938.94 Mn |
| Jun 30, 2025 | 631.91 Mn |
| Mar 31, 2025 | 1.09 Bn |
| Dec 31, 2024 | 929.03 Mn |
| Sep 30, 2024 | 950.05 Mn |
| Jun 30, 2024 | 1.76 Bn |
| Mar 31, 2024 | 843.00 Mn |
| Dec 31, 2023 | 477.01 Mn |
| Sep 30, 2023 | 936.45 Mn |
| Jun 30, 2023 | 2.17 Bn |
| Mar 31, 2023 | 1.98 Bn |
| Dec 31, 2022 | 1.71 Bn |
| Sep 30, 2022 | 991.63 Mn |
| Jun 30, 2022 | 2.11 Bn |
| Mar 31, 2022 | 1.79 Bn |
| Dec 31, 2021 | 1.54 Bn |
| Sep 30, 2021 | 1.80 Bn |